Myocardial infarction with non-ST elevation. Non-ST elevation (NSTEMI) myocardial infarction
Conditions
Interventions
Intervention 1: Intervention group: NSTEMI patients receiving montelukast 10 mg twice daily for one month along with standard treatment. Intervention 2: Control group: NSTEMI patients receiving placeb
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with non-ST-elevation MI according to the American College of Heart criteria Consent to admission to the study Age more than 18 years old No kidney failure under hemodialysis No kidney failure and GFR<30 No thrombocytopenia No severe liver failure with liver enzymes three times more than normal No treatment with corticosteroids or immunosuppressive drugs No treatment with diltiazem or verapamil No history or prone to suicide No previous treatment with Montelukast
Exclusion criteria
Exclusion criteria: Lack of consent to continue the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in hs-CRP serum level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in CBC diff. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Changes in lipid profile. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Changes in Interleukin-6 levels. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Vafa Baradaran Rahimi
Mashhad University of Medical Sciences
Outcome results
None listed